Tag Archives: BIO Investor Forum

As a breast cancer advocate, I am seduced by the lure of translational research and the promises of personalized medicine that will make the one size fits all approach to cancer treatment obsolete and possibly reduce over-treatment, toxicity, and treatment errors. I will be attending the BIO Technology Transfer Symposium and BIO Investor Forum next week and will look forward to hearing insights from biotech industry leaders. The Tech Transfer Symposium will address opportunities and Read More >

The Burrill Report’s Daniel Levine spoke with Jim Greenwood, president and CEO of BIO, about the upcoming Eighth Annual BIO Investor Forum’s opening plenary session on healthcare reform. Greenwood will be moderating the session, “Healthcare Reform: Sustaining Biotech Innovation in a New World.” Listen to the podcast.

Osteologix, Inc. (OLGX.OB) will continue the clinical development for its osteoporosis drug, NB S101 (strontium malonate), in the U.S. and worldwide. Additionally, the company wants to recognize World Osteoporosis Day’s significance and make more people aware of its research dedicated to improving the lives of people with osteoporosis. Read the release.

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) invested in British Canadian Biosciences Corp., a privately held biotechnology company specializing in the development of peptides for the treatment of a variety of conditions, including cancer. Oncolytics has purchased all of the convertible preferred shares of BCBC in exchange for 200,000 common shares of Oncolytics. If converted to common shares, Oncolytics would own 10% of the outstanding BCBC common shares. In addition, Oncolytics has obtained a right, Read More >

Biotech Now’s Tracy Krughoff spoke with Dr. Tim Coetzee, president of Fast Forward, a subsidiary of the National Multiple Sclerosis Society. Fast Forward will be one of the advocacy organizations presenting at the Eighth Annual BIO Investor Forum. Listen now! http://www.bio.org/podcasts/coetzee.wma